Mirvaso® (brimonidine) the first and only treatment targeting the facial redness of rosacea approved by the European Commission

Galderma, a leading global pharmaceutical company exclusively focused on dermatology, today announced that the European Commission has granted Marketing Authorisation in Europe for Mirvaso®...